Lv7
4500 积分 2021-08-04 加入
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma
2个月前
已完结
A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects
3个月前
已完结
Location, location, location: EMD in MM
3个月前
已完结
Location, location, location: EMD in MM
3个月前
已关闭
Bruton's tyrosine kinase: A promising target for treating systemic lupus erythematosus
4个月前
已完结
How I treat triple-class refractory multiple myeloma
4个月前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
4个月前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
4个月前
已完结
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A
4个月前
已完结
Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment
4个月前
已完结
皖公网安备34019202002308
